



Revenio Group Corporation: Interim Report January 1 - June 30, 2013 - STRONG NET SALES AND OPERATING PROFIT GROWTH CONTINUED IN THE SECOND QUARTER

Revenio Group Corporation Stock exchange release August 5, 2013 at 9 a.m

Revenio Group Corporation's Interim Report January 1 - June 30, 2013

STRONG NET SALES AND OPERATING PROFIT GROWTH CONTINUED IN THE SECOND QUARTER

Highlights for April-June 2013:

- * Revenio Health Tech segment showed strong growth with the quarter's sales and operating profit reaching a record high
- * Besides the US markets, the Health Tech segment enjoyed robust demand in the Japanese markets. Similarly, southern Europe continued to show signs of recovery
- * The Revenio Technology and Services segment performed ascendingly in the first half, with the Contact Center business showing the strongest growth and reaching a record high in both net sales and operating profit
- * Positive business deployment seen in H1 is expected to continue during H2
- * The Group's financial guidance for 2013 remains unchanged: In continuing operations, consolidated net sales and operating profit excluding non-recurring items are expected to see year-on-year growth.

Highlights for January-June 2013:

- * Sales and operating profit of the Revenio Health Tech segment showed strong growth
- * Revenio Technology and Services segment saw a year-on-year performance improvement measured by both net sales and operating profit
- * In accordance with the decision made on December 18, 2012, parts of the Done Logistics business were divested on February 7, 2013
- * The Annual General Meeting resolved to pay a dividend of EUR 0.02 (0.02) per share, or EUR 0.20 (0.20) at the current number of shares. The AGM also authorized the Board of Directors to decide on a repayment of capital of up to EUR 1,000,000.00 at a later date
- * The AGM also decided on a reverse share split. As of March 27, 2013, ten old shares will correspond to one new Revenio Group Corporation share
- * After the reporting period on August 5th the Board, according to the authorization given by the AGM, decided on capital repayment of EUR 0.12 per share.

Group key figures:

4-6/2013

- * Net sales EUR 6.9 (5.8) million, an increase of 19.9 percent
- * Operating profit EUR 1.5 (1.0) million, or 21.0 (17.5) percent of net sales
- * Net sales of the Revenio Health Tech segment EUR 3.2 (2.6) million, up 25.8 percent
- * Operating profit of Revenio Health Tech EUR 1.3 (1.1) million, representing 40.1 (41.4) percent of net sales, an increase of EUR 0.2 million, up 21.6 percent
- * Net sales of the Revenio Technology and Services segment EUR 3.7 (3.2) million, up 15.1 percent.
- * Revenio Technology and Services segment's operating profit EUR 0.4 (0.2) million, or 9.6 (6.4) percent of net sales, an increase of EUR 0.2 million, up 67.1 percent

- * Result for discontinued operations EUR 0.0 (-1.6) million, with no impact on the second-quarter result
- * Diluted and undiluted earnings per share, continuing operations, EUR 0.13 (0,06).

1-6/2013

- * Net sales EUR 14.0 (11.6) million, growth 20.5 percent
- * Consolidated operating profit EUR 2.6 (2.2) million , or 18.6 (18.6) percent of net sales
- * Net sales of the Revenio Health Tech segment EUR 6.4 (5.2) million, up 22.4 percent
- * Operating profit of Revenio Health Tech EUR 2.4 (2.2) million, representing 38.5 (42.6) percent of net sales, an increase of EUR 0.2 million, up 10.6 percent
- * Net sales of the Revenio Technology and Services segment EUR 7.7 (6.4) million, up 18.9 percent
- * The segment's operating profit EUR 0.6 (0.4) million, or 7.5 (7.0) percent of net sales, an increase of EUR 0.2 million, up 26.6 percent
- * Result for discontinued operations was EUR 0.0 (-2.1) million, with no impact on the first half-year result.
- * Pre-tax profit, continuing operations, EUR 2.6 (2.0) million
- * Undiluted earnings per share, continuing operations, EUR 0.24 (0.19), and diluted earnings per share, continuing operations, EUR 0.24 (0.19)
- * Cash flow from continuing operations EUR 2.7 (1.8) million.

President & CEO Olli-Pekka Salovaara:

"The Revenio Group performed very well in the first half measured by both sales and profitability. As stated in our strategy, our focus this year will be on creating growth opportunities in the Health Tech segment while increasing the segment's operating profit. Good net sales growth and excellent profitability achieved in the first half will take us one step closer to our goal, which is to make Icare the leading tonometer supplier globally.

Both in net sales and operating profit, our Health Tech segment reached an all-time high in the review period. The United States continues to be a major market area for us. Sales launched in Russia a year before continued to grow, and the signs of recovery seen in Southern Europe grew stronger. Asia, particularly Japan, is emerging as a significant market alongside the United States and Europe. The sales of disposable probes for tonometers grew significantly as a result of the continued and increasing use of the devices already sold. The expanding stock of sold equipment will offer the segment excellent future sales opportunities for replacement devices. The segment's net sales rose by 22.4 percent in January-June 2013 to EUR 6.4 (5.2) million.

In line with our strategy, the Technology and Services segment will focus on securing profitable growth. The Contact Center business, which has been on a growth track for the past three years, accounted for the strongest performance in the first half. The Rigid Inflatable Boats business completed several demanding customer deliveries, and was able to grow its net sales and profitability. Similarly, our Software business performed strongly in the first half. The segment's total net sales in the January-June period amounted to EUR 7.7 (6.4) million; an increase of 18.9 percent.

During the review period, we moved all of our operations in the Helsinki region under one roof. Our new facilities are located in the Vantaa Plaza Business Park. Revenio Group Corporation, Icare Finland Oy and Midas Touch Oy also relocated to the new premises. Sharing the same business location and facilities will open up new opportunities for operational efficiency enhancement and better communication. "

APRIL-JUNE 2013 COMMENTS:

REVENIO HEALTH TECH

Revenio's Health Tech segment consists of Icare Finland, which specializes in the development, manufacture, and sale of tonometers.

Currently the segment's main markets are in North America, Europe, Russia and

selected Asian countries, such as Japan and India. Market areas that we still haven't tapped into and that offer considerable potential include South America and China.

In April-June 2013 the Revenio Health Tech segment's net sales rose by 25.8 percent to EUR 3.2 (2.6) million, which represents an all-time sales record.

The market situation remained good throughout the review period. Sales grew in all geographic regions, with the United States and Japan accounting for the most vigorous growth. The Southern European markets also got back on growth track during the first half. In Asia, sales were brisk in Taiwan, Thailand and Hong Kong. During the review period, a trading license was granted to the segment's products in Mexico.

Distribution channels are crucial for successful global sales. During the period, some changes were made to distribution channels to support geographic expansion.

Icare tonometers can also be used to measure intraocular pressure in animals. This product group showed strong growth during the period, especially in the United States and Europe.

Probe sales were up by 24 percent, reflecting the continued and increasing use of devices already sold. During the review period probe sales stood for one fifth of the total sales.

Tonometer user experiences published during the review period together with Icare Finland Oy's determined marketing efforts contributed to the strong sales performance. Icare tonometers were showcased in a number of trade events intended for specialists. This proved to be an effective marketing channel.

Icare tonometer features were improved during the review period to further cement Icare's strong market position and to maintain its competitive edge. With the expanding stock of sold devices, the demand for productized maintenance services is also increasing.

REVENIO TECHNOLOGY AND SERVICES

On December 1, 2012, the Revenio Technology and Services segment was formed from four Group businesses and companies, and some functions of the Group's parent company. The businesses included in this segment are the Contact Center business, Rigid Inflatable Boats business, Information Displays business, and Software business.

In line with its strategy, Revenio's Technology and Services segment is focusing on organic growth, efficiency, and profitability improvement.

In April-June, the segment recorded net sales of EUR 3.7 (3.2) million; an increase of 15.1 percent compared to the same period last year.

The Contact Center business performed well with significant net sales growth and a healthy operating profit. New inbound accounts had a major impact on the financial performance. The market environment is challenging, and the new bans on telemarketing have forced some players to exit the industry. Competition for profitable accounts is extremely tough, making production-promoting sales efforts as well as the efficient implementation of customer assignments key factors for success. Previous investments in production technology in this line of business have clearly enhanced production efficiency and service quality.

During the review period, the Rigid Inflatable Boats business was able to improve its net sales and profitability. Main operational focus was on the delivery of existing orders. The Finnish Navy placed a new order worth approximately EUR 0.5 million.

The Information Displays business fell slightly short of the previous year's net sales and operating profit. New orders received during the period primarily consisted of supplements ordered by existing customers and of domestic deliveries. At the end of the review period, a Helsinki-based shopping center Kaari placed an order for a parking guidance solution. Delivery is scheduled for

the second half of the year.

In the Software Business, main focus at the start of the period was on bringing major customer projects commenced last year on line, and on further development of systems installed for customer use. At the end of the period, expansion orders for new destinations were placed by existing customers.

Net sales and segment's margin excluding non-recurring items were as follows:

| | Net Sales | | Net Sales | | Segment profit margin | | Segment profit margin | |
|---------------------------------|-----------|---------|-----------|---------|-----------------------|----|-----------------------|----|
| | 1-6/2013 | | 1-6/2012 | | 1-6/2013 | | 1-6/2012 | |
| | MEUR | share-% | MEUR | share-% | MEUR | % | MEUR | % |
| Revenio Health Tech | 6.4 | 45 | 5.2 | 45 | 2.4 | 38 | 2.2 | 42 |
| Revenio Technology and Services | 7.7 | 55 | 6.4 | 55 | 0.6 | 8 | 0.4 | 6 |
| Total | 14.0 | 100 | 11.6 | 100 | 3.0 | 22 | 2.6 | 22 |
| Parent company expenses | | | | | -0.4 | | -0.4 | |
| Operating Profit, Group Total | | | | | 2.6 | 19 | 2.2 | 19 |

The net sales, margin, and profit, by segment and quarter

, excluding non-recurring items, were as follows:

| MEUR | Q2/13 | Q1/13 | Q4/12 | Q3/12 | Q2/12 | Q1/12 |
|---------------------------------|-------|-------|-------|-------|-------|-------|
| Net sales: | | | | | | |
| Revenio Health Tech | 3.2 | 3.1 | 3.2 | 2.6 | 2.6 | 2.6 |
| Revenio Technology and Services | 3.7 | 4.0 | 4.5 | 3.4 | 3.2 | 3.2 |
| Total | 6.9 | 7.1 | 7.7 | 6.1 | 5.8 | 5.8 |
| Segment profit margin: | | | | | | |
| Revenio Health Tech | 1.3 | 1.1 | 1.2 | 1.0 | 1.0 | 1.2 |
| Revenio Technology and Services | 0.4 | 0.2 | 0.5 | 0.5 | 0.2 | 0.3 |
| Total | 1.7 | 1.3 | 1.7 | 1.6 | 1.3 | 1.5 |
| Parent co. expenses | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 |
| Operating profit | 1.5 | 1.2 | 1.4 | 1.4 | 1.0 | 1.2 |
| Operating profit-% | 20 | 16 | 18 | 22 | 17 | 20 |

PERSONNEL

During the review period, the number of personnel employed by the Group in continuing operations averaged 227 (209). At the end of the period, the number of employees stood at 245 (227).

The average number of personnel employed by the Group during the period by segment:

| | 30 June 2013 | 31 June 2012 | Change |
|------------------------------------|--------------|--------------|--------|
| Revenio Health Tech | 17 | 13 | 4 |
| Revenio Technology and Services | 206 | 192 | 14 |
| Parent Company | 4 | 4 | 0 |
| Group Total | 227 | 209 | 18 |

Wages, salaries, and other remuneration paid for continuing operations during the period totaled EUR 3.9 (3.5) million.

NET SALES AND FINANCIAL PERFORMANCE

Consolidated net sales from the Revenio Group's continuing operations for the period January 1-June 30, 2013, totaled EUR 14.0 (11.6) million, representing net sales growth of 20.5 percent.

Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations amounted to EUR 3.0 (2.5) million, or 21.3 (21.6) percent of net sales.

Consolidated operating profit (EBIT) from continuing operations was EUR 2.6 (2.2) million, representing 18.6 (18.6) percent of net sales. Profit before taxes for continuing operations totaled EUR 2.6 (2.0) million, or 18.5 (16.9) percent of net sales. Net result for the period for continuing operations was EUR 1.9 (1.5) million, or 13.7 (12.9) percent of net sales. Net result for discontinued operations totaled EUR 0.0 (-2.1) million. Net profit for the period totaled EUR 1.9 (-0.6) million.

Undiluted earnings per share for continuing operations were EUR 0.24 (0.19), while dilution-adjusted earnings per share came to EUR 0.24 (0.19). For discontinued operations, the undiluted and diluted earnings per share were EUR 0.00 (-0.27). Dilution-adjusted earnings per share for continuing and discontinued operations during the period were EUR 0.24 (-0.07). Equity per share was EUR 2.01 (1.87).

During the review period, the consolidated net sales of continuing operations saw a year-on-year increase of 20.5 percent. The Revenio Health Tech segment as well as the Revenio Technology and Services segment's Contact Center and Rigid Inflatable Boats businesses accounted for the strongest net sales growth.

The Revenio Health Tech segment was able to increase its operating profit compared to the same period a year earlier. Some of the additional margin generated by the net sales growth was used for business development. Regardless, the segment's operating profit grew to EUR 2.4 (2.2) million. In the Technology and Services segment, operating profit rose to EUR 0.6 (0.4) million.

On December 18, 2012, the Group decided to divest Done Logistics Oy. The company has since been categorized as 'discontinued operations' in consolidated reporting. A part of Done Logistics' business operations were sold on February 7th 2013, since the name of the company has been Kauhajoen Sisälogistiikka Oy. The role of the company is to complete the remaining projects in Norway, which is expected to happen in 2014. The result for discontinued operations in 2013 covers the result for Kauhajoen Sisälogistiikka Oy and any changes in provisions for winding up operations.

BALANCE SHEET, FINANCIAL POSITION AND INVESTMENTS

The consolidated balance sheet total stood at EUR 23.3 (23.7) million on June 30, 2013.

Shareholders equity came to EUR 15.8 (14.4) million. At the end of the review period, interest-bearing net liabilities amounted to EUR -2.7 (-0.3) million and gearing stood at -17.2 (-1.9) percent. The consolidated equity ratio was 69.8 (61.6) percent. The Group's liquid assets amounted to EUR 4.5 (4.0) million at the end of the review period.

Thanks to favorable trends in operations, the Group's financial position remained stable throughout the review period. No financing was raised through borrowed capital during the review period. Revenio's financial position was also bolstered by funds received from shares subscribed to via options, a total of EUR 0.7 million.

Cash flow from continuing operations totaled EUR 2.7 (1.8) million.

The Group's purchases of PPE and intangible assets totaled EUR 0.3 (0.3) million. These investments concentrated on product development, information technology, and software.

SHARES, SHARE CAPITAL AND MANAGEMENT HOLDINGS

On June 30, 2013, the Revenio Group Corporation's fully paid-up share capital registered with the Trade Register was EUR 5,314,918.67 and the number of shares totaled 7,838,909. During the review period, the number of shares increased by 145,936 following subscriptions made on the basis of the 2007 stock option scheme. Series 2007A option rights were used to subscribe for 100,624 shares, 2007B option rights to subscribe for 14,812 shares and 2007C options rights to subscribe for 30,500 shares. The subscription period for 2007A options ended on May 1, 2013. The outstanding 2007B and 2007C options can be used to subscribe for a total of 145,688 shares until the close of the subscription period on November 1, 2014 (2007B) and May 1, 2016 (2007C).

The company has one class of share, and all shares confer the same voting rights and an equal right to dividends and the company's funds.

On June 30, 2013, the President & CEO and members of the Board of Directors held 6.8 percent of the company's shares (536,149 shares) and 0.0 percent of the option rights.

CHANGES IN SHAREHOLDING

On May 10, 2013, it was announced that Joensuun Kauppa ja Kone Oy's share of the total number of shares and voting rights in Revenio Group Corporation had exceeded one twentieth (1/20). Joensuun Kauppa ja Kone Oy's new holding represents 5.02 percent of Revenio Group Corporation's shares and votes. Joensuun Kauppa ja Kone Oy holds 389,626 Revenio Group Corporation shares.

OPTION RIGHTS

On the basis of the share issue authorization approved by the Annual General Meeting of April 3, 2007, the Board of Revenio Group Corporation decided, on November 23, 2007, on a new corporate option scheme comprising a maximum of 3,684,365 option rights. Ten option rights entitle the holder to subscribe for one (1) Revenio Group Corporation share. Against the total number of the company's shares on June 30, 2013, the proportion of shares to be subscribed for on the basis of the option rights issued represents a maximum of 1.9 percent of the company's shares and votes, once all new shares subscribed for with these option rights have been registered.

New shares subscribed for via the option program entitle the holder to a dividend from the subscription year onwards.

The option rights have been divided into three series: Series A (1,684,365), Series B (1,000,000) and Series C (1,000,000). The subscription periods for options are as follows: Series A, May 1, 2009-May 1, 2013; Series B, November 1, 2010-November 1, 2014; and Series C, May 1, 2012-May 1, 2016. The share subscription price will be the trade-weighted average price during the period November 1-30, 2007 multiplied by ten (EUR 5.99, Series A), April 1-30, 2009 multiplied by ten (EUR 2.47, Series B), and November 1-30, 2010 multiplied by ten (EUR 2.41, Series C).

No new options were issued to personnel during the review period.

TRADING ON NASDAQ OMX HELSINKI

During the period January 1- June 30, 2013, the Revenio Group Corporation's share turnover on the NASDAQ OMX Helsinki exchange totaled EUR 6.1 (6.7) million, representing 1.7 (1.5) million shares or 22.2 (19.9) percent of all shares outstanding after the reverse share split of March 27, 2013.

The highest trading price was EUR 8.1 (5.0) and the lowest EUR 4.1 (3.3). At the end of the review period, the closing price was EUR 7.6 (3.6), and the average share price EUR 3.5 (4.4). The Revenio Group Corporation's market value stood at EUR 59.2 (27.7) million on June 30, 2013. These figures take into account the effects of the reverse share split.

RISK MANAGEMENT

The Group's major business risks are presented in its financial statement bulletin of February 8, 2013. No changes in these risks have occurred since the bulletin's release.

ANNUAL GENERAL MEETING AND BOARD AUTHORIZATIONS IN EFFECT

The Annual General Meeting held on March 21, 2013 approved the company's financial statements and discharged the President & CEO and the members of the Board of Directors from liability for the financial year January 1-December 31, 2012.

The AGM re-elected Pekka Tammela and Rolf Fryckman as members of the Board, and elected Ari Kohonen as a new member. The AGM decided that the Chairman of the Board should be paid a fee of EUR 36,000 per annum and other Board members EUR 18,000 per annum. 60 percent of the fee is paid as monetary compensation and 40 percent in company shares.

The AGM re-elected PricewaterhouseCoopers Oy, Authorized Public Accountants, as the company's auditors with Juha Tuomala, Authorized Public Accountant, as principal auditor.

The AGM accepted the Board's proposal on profit distribution, according to which the profit for the financial period, EUR 1,545,444.10, will be added to retained earnings, and a dividend of EUR 0.02 per share will be paid, totaling EUR 1,536,675.74.

The AGM authorized the Board of Directors to decide on the acquisition of a maximum of 771,107 of the company's own shares, either in one or several installments, using the company's unrestricted equity, in which case any buyback will reduce the amount of distributable earnings.

The AGM canceled the Board of Directors' valid unexercised share-issue authorizations, and authorized the Board to decide to issue a maximum of 3,000,000 shares or to grant special rights (including stock options) entitling to shares, as referred to in Section 1 of Chapter 10 of the Limited Liability Companies Act, in one or several installments. This authorization was granted for use in financing and implementing any prospective corporate acquisitions or other transactions, for implementing the company's share-based incentive plans, or for other purposes determined by the Board. The Board has the right to decide on all terms and conditions governing said share issue and the granting of special rights, including the subscribers or grantees of the special rights, and the consideration payable. The authorization also includes the right to waive shareholders' pre-emptive subscription rights and covers the issue of new shares

and the transfer of any shares that may be held by the company. This authorization is valid until April 30, 2014.

BOARD OF DIRECTORS AND AUDITORS

As of March 21, 2013, the Revenio Group Corporation's Board of Directors consists of: Pekka Tammela, M.Sc. (Econ.), Authorized Public Accountant, partner in Pajamaa Partners Oy (Chairman); Rolf Fryckman, optician, Chairman of the Board of Eyemaker's Finland Oy; and - a new member as of March 21, 2013 - Ari Kohonen, M.Sc. (Eng.), M.Sc. (Econ.). Kohonen is also Chairman of the Board of Gerako Oy.

PricewaterhouseCoopers Oy, Authorized Public Accountants, serves as the company's auditor, with Juha Tuomala, Authorized Public Accountant, as principal auditor.

MAJOR EVENTS AFTER THE REVIEW PERIOD

The Annual General Meeting of Revenio Group Corporation on March 21st authorized the Board of Directors to decide on, at its own discretion, a capital repayment from the invested unrestricted equity reserve. The maximum amount of equity distributed to shareholders on the basis of the authorization would be EUR 1,000,000.00.

Based on this authorization, The Board has today decided on a capital repayment of EUR 0.12 per share. This decision is based on the favourable development of the company's result and financial position as well as maintaining the company's capital structure in line with the set financial targets.

OUTLOOK FOR 2013

In continuing operations, consolidated net sales and operating profit excluding non-recurring items are expected to see year-on-year growth.

STATEMENT OF ACCOUNTING POLICIES

This interim report has been prepared in compliance with the requirements of IAS 34 Interim Financial Reporting. The figures are unaudited.

| GROUP KEY FIGURES AND RATIOS (MEUR) | 1-6/2013 | 1-6/2012 | 1-12/2012 |
|---|----------|----------|-----------|
| Net sales, continuing operations | 14.0 | 11.6 | 25.4 |
| Ebitda, continuing operations | 3.0 | 2.5 | 5.7 |
| Ebitda-%, continuing operations | 21.3 | 21.6 | 22.5 |
| Operating profit, continuing operations | 2.6 | 2.2 | 4.9 |
| Operating profit-%, continuing operations | 18.6 | 18.6 | 19.4 |
| Pre-tax profit, continuing operations | 2.6 | 2.0 | 4.7 |
| Pre-tax profit-%, continuing operations | 18.5 | 16.9 | 18.5 |
| Net profit from discontinued operations | 0.0 | -2.1 | -4.8 |
| Net profit, continuing operations | 1.9 | 1.5 | -0.3 |
| Net profit-%, continuing operations | 13.7 | 12.9 | -1.1 |
| Gross capital expenditure | 0.3 | 0.3 | 0.3 |
| Gross capital expenditure-% | 1.9 | 2.9 | 1.1 |

| | | | |
|--|-------|-------|-------|
| R&D costs | 0.1 | 0.1 | 0.4 |
| R&D costs-% from net sales | 1.0 | 1.2 | 1.4 |
| Gearing-% | -17.2 | -1.9 | -12.2 |
| Equity ratio-% | 69.8 | 61.6 | 62.2 |
| Return on investment-% (ROI) | 25.9 | -3.8 | 0.4 |
| Return on equity-% (ROE) | 25.1 | -1.9 | -1.8 |
| Undiluted earnings per share, EUR, continuing operations | 0.24 | 0.19 | 0.59 |
| Diluted Earnings per share, EUR, continuing operations | 0.24 | 0.19 | 0.59 |
| Undiluted earnings per share, EUR, discontinued operations | 0.00 | -0.27 | -0.63 |
| Diluted Earnings per share, EUR, discontinued operations | 0.00 | -0.27 | -0.63 |
| Equity per share, EUR | 2.01 | 1.87 | 1.91 |
| Average no. of employees, continuing operations | 227 | 209 | 198 |
| Cash flow from operating activities | 2.7 | 1.8 | 4.8 |
| Cash flow from discontinued operations | -0.6 | -2.6 | -4.0 |
| Cash flow from investing activities | -0.3 | 0.0 | -0.1 |
| Net cash used in financing activities | -2.3 | 0.4 | -0.2 |
| Total cash flow | -0.5 | -0.4 | 0.5 |

| CONSOLIDATED COMPREHENSIVE | 1-6/2013 | 1-6/2012 | 1-12/2012 |
|---|----------|----------|-----------|
| INCOME STATEMENT (MEUR) | | | |
| NET SALES | 14.0 | 11.6 | 25.4 |
| Other operating income | 0.0 | 0.1 | 0.1 |
| Materials and services | -3.9 | -2.7 | -6.9 |
| Employee benefits | -4.7 | -4.2 | -8.4 |
| Depreciation/amortization | -0.4 | -0.3 | -0.8 |
| Other operating expenses | -2.5 | -2.2 | -4.5 |
| OPERATING PROFIT, CONTINUING OPERATIONS | 2.6 | 2.2 | 4.9 |
| Share of associates' results | 0.0 | 0.0 | 0.0 |
| Financial expenses (net) | 0.0 | -0.2 | -0.2 |
| PRE-TAX PROFIT, CONTINUING OPERATIONS | 2.6 | 2.0 | 4.7 |
| Income tax expense | -0.7 | -0.5 | -0.1 |
| Net profit from continuing operations | 1.9 | 1.5 | 4.6 |
| Net profit from discontinued operations | 0.0 | -2.1 | -4.8 |

| | | | |
|--|------|-------|-------|
| NET PROFIT | 1.9 | -0.6 | -0.3 |
| Other comprehensive income items | 0.0 | 0.0 | 0.0 |
| Income tax expense for comprehensive income | 0.0 | 0.0 | 0.0 |
| Other comprehensive income items after taxes | 0.0 | 0.0 | 0.0 |
| TOTAL COMPREHENSIVE INCOME | 1.9 | -0.6 | -0.3 |
| Net profit attributable to: | | | |
| Parent company shareholders | 1.9 | 0.6 | -0.3 |
| Total comprehensive income attributable to: | | | |
| Parent company shareholders | 1.9 | -0.6 | -0.3 |
| Earnings per share, undiluted, EUR, continuing operations | 0.24 | 0.19 | 0.59 |
| Earnings per share, diluted, EUR, continuing operations | 0.24 | 0.19 | 0.59 |
| Earnings per share, undiluted, EUR, discontinued operations | 0.00 | -0.27 | -0.63 |
| Earnings per share, diluted, EUR, discontinued operations | 0.00 | -0.27 | -0.63 |

CONSOLIDATED COMPREHENSIVE

| INCOME STATEMENT (MEUR) | 4-6/2013 | 4-6/2012 |
|---|----------|----------|
| NET SALES | 6.9 | 5.8 |
| Other operating income | 0.0 | 0.1 |
| Materials and services | -1.8 | -1.5 |
| Employee benefits | -2.3 | -2.0 |
| Depreciation/amortization | -0.2 | -0.2 |
| Other operating expenses | -1.2 | -1.2 |
| OPERATING PROFIT, CONTINUING OPERATIONS | 1.4 | 1.0 |
| Share of associates' results | 0.0 | 0.0 |
| Financial expenses (net) | 0.0 | -0.1 |
| PRE-TAX PROFIT, CONTINUING OPERATIONS | 1.4 | 0.9 |
| Income tax expense | -0.4 | -0,2 |
| Net profit from continuing operations | 1.0 | 0.8 |
| Net profit from discontinued operations | 0.0 | -1.6 |
| NET PROFIT | 1.0 | -0.8 |
| Other comprehensive income items | 0.0 | 0.0 |
| Income tax expense for comprehensive income | 0.0 | 0.0 |

| | | |
|---|-----|------|
| Other comprehensive income items | | |
| after taxes | 0.0 | 0.0 |
| TOTAL COMPREHENSIVE INCOME | 1.0 | -0.8 |
| Net profit attributable to: | | |
| Parent company shareholders | 1.0 | -0.8 |
| Total comprehensive income attributable to: | | |
| Parent company shareholders | 1.0 | -0.8 |

CONSOLIDATED BALANCE SHEET (MEUR)

| | 30 June 2013 | 30 June 2012 | 31 Dec 2012 |
|---------------------------------------|--------------|--------------|-------------|
| ASSETS | | | |
| NON-CURRENT ASSETS | | | |
| Property, plant and equipment | 1.5 | 1.6 | 1.6 |
| Goodwill | 8.1 | 8.1 | 8.1 |
| Intangible assets | 0.6 | 0.8 | 0.6 |
| Shares in associates | 0.0 | 0.0 | 0.0 |
| Deferred tax assets | 0.9 | 1.8 | 1.6 |
| TOTAL NON-CURRENT ASSETS | 11.2 | 12.3 | 12.0 |
| CURRENT ASSETS | | | |
| Inventories | 1.7 | 1.2 | 1.3 |
| Trade and other receivables | 4.3 | 3.6 | 4.8 |
| Cash and cash equivalents | 4.5 | 4.0 | 5.0 |
| TOTAL CURRENT ASSETS | 10.5 | 8.8 | 11.2 |
| Non-current assets held | | | |
| for sale | 1.7 | 2.6 | 1.8 |
| TOTAL ASSETS | 23.3 | 23.7 | 25.0 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | |
| SHAREHOLDERS' EQUITY | | | |
| Share capital | 5.3 | 5.3 | 5.3 |
| Share premium | 2.4 | 2.4 | 2.4 |
| Fair value reserve | 0.3 | 0.3 | 0.3 |
| Invested unrestricted capital reserve | 7.9 | 7.0 | 7.1 |
| Retained earnings/loss | -0.1 | -0.7 | -0.4 |
| TOTAL EQUITY, attributable to holders | | | |

| | | | |
|---|------|------|------|
| of parent company equity | 15.8 | 14.4 | 14.7 |
| TOTAL SHAREHOLDERS' EQUITY | 15.8 | 14.4 | 14.7 |
| LIABILITIES | | | |
| NON-CURRENT LIABILITIES | | | |
| Deferred tax liabilities | 0.2 | 0.2 | 0.2 |
| Provisions | 0.1 | 0.1 | 0.1 |
| Financial liabilities | 1.0 | 2.7 | 1.4 |
| TOTAL LONG-TERM LIABILITIES | 1.3 | 3.0 | 1.7 |
| CURRENT LIABILITIES | | | |
| Advance payments | 0.8 | 0.4 | 1.4 |
| Trade and other payables | 3.5 | 1.1 | 3.3 |
| Financial liabilities | 0.8 | 1.0 | 1.8 |
| TOTAL SHORT-TERM LIABILITIES | 5.1 | 2.5 | 6.5 |
| Long-term liabilities held for sale | 1.1 | 3.8 | 2.1 |
| TOTAL LIABILITIES | 7.5 | 9.3 | 10.3 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 23.3 | 23.7 | 25.0 |

CONSOLIDATED STATEMENT OF CHANGE IN EQUITY (MEUR)

| | Share capital | Share Premium | Other Reserves | Retained Earnings | Total Equity |
|-------------------------------|------------------|------------------|-------------------|----------------------|-----------------|
| Balance 1 Jan 2013 | 5.3 | 2.4 | 7.4 | -0.4 | 14.7 |
| Dividend distribution | 0.0 | 0.0 | 0.0 | -1.6 | -1.6 |
| Option rights utilized | 0.0 | 0.0 | 0.8 | 0.0 | 0.8 |
| Net profit | 0.0 | 0.0 | 0.0 | 1.9 | 1.9 |
| Balance 30 June 2013 | 5.3 | 2.4 | 8.2 | -0.1 | 15.8 |
| | Share capital | Share Premium | Other Reserves | Retained Earnings | Total Equity |
| Balance 1 Jan 2012 | 5.3 | 2.4 | 7.3 | 1.3 | 16.4 |
| Dividend distribution | 0.0 | 0.0 | 0.0 | -1.5 | -1.5 |
| Options expense adjustment | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| Net profit | 0.0 | 0.0 | 0.0 | -0.6 | -0.6 |

Balance 30 June 2012 5.3 2.4 7.4 -0.7 14.4

CONSOLIDATED CASH FLOW STATEMENT (MEUR) 1-6/2013 1-6/2012 1-12/2012

| | | | |
|---|------|------|------|
| Net profit | 1.9 | -0.6 | -0.3 |
| Adjustments to net profit | 1.4 | 3.1 | 5,2 |
| Change in working capital | -0.6 | -0.7 | -0.1 |
| Interest paid | 0.0 | 0.0 | -0.1 |
| Interest received | 0.0 | 0.0 | 0.0 |
| CASH FLOW FROM OPERATING ACTIVITIES | 2.7 | 1.8 | 4.8 |
| Cash flow from discontinued operations | -0.6 | -2.6 | -4.0 |
| Sales of subsidiaries and associates' shares (net) | 0.0 | 0.2 | 0.2 |
| Purchase of PPE | -0.3 | -0.2 | -0.3 |
| Purchase of Intangible assets | 0.0 | 0.0 | 0.0 |
| NET CASH USED IN INVESTING ACTIVITIES | -0.3 | 0.0 | -0.1 |
| Used options rights | 0.8 | 0.0 | 0.0 |
| Paid dividends | -1.6 | -1.5 | -1.5 |
| Repayments of long-term borrowings | -1.4 | -1.0 | -1.7 |
| Long-term loans received | 0.0 | 3.0 | 3.2 |
| Finance lease principal payment | -0.1 | -0.1 | -0.1 |
| Loans for associated companies granted | 0.0 | 0.0 | -0.1 |
| NET CASH USED IN FINANCING ACTIVITIES | -2.3 | 0.4 | -0.2 |
| Net change in cash and equivalents | -0.5 | -0.4 | 0.5 |
| Cash and equivalents. period-start | 5.0 | 4.4 | 4.4 |
| Cash and equivalents. period-end | 4.5 | 4.0 | 5.0 |

NET SALES AND OPERATING PROFIT BY QUARTER (MEUR)

| | Q2/2013 | Q1/2013 | Q4/2012 | Q3/2012 | Q2/2012 | Q1/2012 |
|-----------------|---------|---------|---------|---------|---------|---------|
| Net sales | 6.9 | 7.1 | 7.7 | 6.1 | 5.8 | 5.8 |
| Oper. Profit | 1.5 | 1.2 | 1.4 | 1.4 | 1.0 | 1.2 |
| Oper. profit.-% | 20 | 16 | 18 | 23 | 17 | 20 |

MAIN SHAREHOLDERS 30 June 2013

| | No. of shares | % |
|--------------------------|---------------|------|
| 1. Merivirta Jyri | 1000,000 | 13 % |
| 2. Eyemakers' Finland Oy | 500,000 | 6 % |

| | | |
|---|---------|-----|
| 3. Joensuun Kauppa ja Kone Oy | 407,048 | 5 % |
| 4. Sijoitusrahasto Evli Suomi Osake | 371,076 | 5 % |
| 5. Keskinäinen Eläkevakuutusyhtiö Etera | 350,000 | 5 % |
| 6. Gerako Oy | 340,000 | 4 % |
| 7. Alpisalo Mia | 294,815 | 4 % |
| 8. Salovaara Olli-Pekka | 151,330 | 2 % |
| 9. Kirkon Keskusrahasto | 124,081 | 2 % |
| 10. Keskinäinen vakuutusyhtiö Fennia | 89,822 | 1 % |

Revenio Group Corporation

Board of Directors

For additional information:

CFO Pekka Raatikainen, tel. +358 50 5534094

olli-pekka.salovaara@revenio.fi

<http://www.revenio.fi>

DISTRIBUTION:

NASDAQ OMX Helsinki

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy. The widely patented Icare product family is the current cornerstone of the Group's success. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers.

The Revenio Group also includes other business operations, which are grouped under the Technology and Services segment. This segment's operations have a shared global market and represent the cutting edge of technology products and services in their industry. These businesses are extremely profitable in their industries and generate positive cash flow.

In 2012, the Revenio Group's net sales totaled EUR 25.4 million, with its operating margin standing at 19.4 percent. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.

[HUG#1719340]